Skip to main content
Premium Trial:

Request an Annual Quote

Helomics Completes Restructuring to Clinical CRO

NEW YORK (GenomeWeb) – Helomics said today that it has completed the final phase of a restructuring process designed to establish the company as a clinical contract research and clinical products organization.

The Pittsburgh-based company will now provide product enhancement and clinical laboratory services — including comprehensive tumor profiling using proprietary cell-based products and services — to customers in the healthcare industries. Patients who consent to undergo sample testing at Helomics have the opportunity to further cancer research and the development of new therapies and diagnostics through Helomics' technology development and industry partnerships, the firm added.

Gerald Vardzel, Jr. will serve as president and CEO of the company, replacing Neil Campbell, who is no longer with the firm. Campbell had joined the firm in late 2014, around the time the company changed its name to Helomics from Precision Therapeutics.

Helomics made the announcement a week after the Pittsburgh Post-Gazette reported that a group of investors, including Vardzel, had acquired the firm from Stamford, Connecticut-based healthcare investment firm HealthCare Royalty Partners. The company did not disclose financial details of the acquisition.

In February, Helomics launched two new servicesan expansion of its live-cell analysis platform called CellFx, and a tumor shedding analysis called Defender that is intended to serve as a virtual parallel to liquid biopsies.

These services are part of the company's comprehensive tumor profiling offering. Helomics also offers two genetic tests for disease recurrence: GeneFx Colon, a microarray-based test for stage II colon cancer patients; and GeneFx Lung, an array-based 15-gene assay, licensed from Almac Diagnostics and Med BioGene, respectively.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.